Oncolytics Biotech Inc.
ONCY
Positions held
Your positionsONCY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $71.38M | Enterprise value | $65.75M | Trailing P/E | — | Forward P/E | -2.76 |
| PEG | — | Price / book | -11.11 | Beta | 1.16 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | -2.1% | Debt / equity | — |
| Current ratio | 1.35 | Free cash flow | -$12.01M | Analyst recommendation | buy | Mean target | $4.15 |
| 52w high | $1.32 | 52w low | $0.54 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$9.4M | -$9.2M | -$9.2M | -$10.3M | -$5.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.4M | -$9.3M | -$9.7M | -$9.9M | -$4.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$28.8M | -$22.8M | -$20.9M | -$18.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$28.7M | -$25.5M | -$25.5M | -$19.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
2026-09-28 · KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
2026-09-16 · 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
2026-08-28 · 3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
2026-08-27 · ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC
2026-08-19 · Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials
2026-08-18 · Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
2026-07-20 · Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment
2026-07-20 · Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
2026-07-16 · ONCY: Seeking Registration Pathway for Part B of REO 033 Trial
Price (daily)
Full chart · RSI · MACD · patterns